Novel Therapeutic Modality: Azitra is pioneering a first-in-class approach by using genetically engineered live bacteria as a therapeutic modality for skin diseases, offering a distinct mechanism of action compared to conventional drugs.

Proprietary Bio-Engineering Platform: The company possesses a proprietary platform for engineering commensal skin microbes, enabling the development of targeted, living therapeutics with specific functions to treat complex dermatological conditions.

Addressing High Unmet Medical Needs: Azitra focuses on severe and rare skin diseases like Netherton Syndrome, where current treatment options are limited and often ineffective, positioning them to capture significant market share upon approval.